Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors

NCT00418938 is registered in ClinicalTrials.gov with Amgen as lead sponsor.

NCT NCT00418938
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00418938 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-center, Open-label, Randomized, Phase 2 Clinical Trial Evaluating Safety and Efficacy of FOLFIRI With Either Panitumumab or Bevacizumab as Second-Line Treatment in Subjects With Metastatic Colorectal Cancer With Wild-type KRAS Tumors
Lead sponsor
Amgen
Phase
Phase 2
Overall status
Completed
Start date
November 1, 2006
Completion date
April 1, 2013
Enrollment
266 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

cancer, colon cancer, colorectal cancer, metastatic cancer, metastatic colorectal cancer, rectal cancer